Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis.
The reduction in plaque volume during stent implantation is associated with the release of particulate debris and plaque-derived soluble substances. We studied the potential release of the proinflammatory cytokine TNF-alpha into the coronary circulation and whether such release is related to the reduction in plaque volume and, possibly, a predictor for restenosis. In 18 male patients (n = 24 stents) with severe stenosis in a saphenous vein aortocoronary bypass graft (SVG), we used a distal balloon occlusion-aspiration device during stent implantation. The aspirate TNF-alpha levels were determined before and after stent implantation and related to the angiographic and intravascular ultrasound-assessed severity of stenosis and restenosis. We found that TNF-alpha is, indeed, released into the aspirate of stented SVG (9 +/- 1 and 28 +/- 3 pg/ml before and after stent implantation, respectively, P < 0.0001) and that such release is related to the reduction in plaque volume (r = 0.88, P < 0.0001) and associated with restenosis after 5 mo (r = 0.71, P = 0.001). The periprocedural release of plaque-derived TNF-alpha possibly represents the amount and activity of the atherosclerotic process and might be a predictor for restenosis.
Böse
Dirk
D
Department of Cardiology, University of Essen Medical School, Hufelandstrasse 55, 45147 Essen, Germany.
Leineweber
Kirsten
K
Konorza
Thomas
T
Zahn
Andreas
A
Bröcker-Preuss
Martina
M
Mann
Klaus
K
Haude
Michael
M
Erbel
Raimund
R
Heusch
Gerd
G
D050197:Atherosclerosis / Q000378:metabolism* / Q000601:surgery*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D006083:Graft Occlusion, Vascular / Q000209:etiology* / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012501:Saphenous Vein / Q000378:metabolism* / Q000637:transplantation; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D014409:Tumor Necrosis Factor-alpha